China’s Pharmaceutical Industry Growth And Profit Top All Industries
This article was originally published in PharmAsia News
Executive Summary
China's Ministry of Industry and Information Technology revealed that in the first two months of 2009, the local pharmaceutical industry's value add, total output value and sales value increased 13.5 percent, 17.6 percent and 16.6 percent, respectively, when compared to the same period last year. Profits amounted to RMB 11.5 billion, a jump of 22.4 percent. These figures put the pharmaceutical industry's growth and profit rates top among all industries in China. Chemical raw materials and formulations, herbal slice and patent TCM, bioproducts and biochemical products, as well as hygiene materials and medical products increased 14 percent, 20.4 percent, 21.1 percent and 32.5 percent, respectively. However, export growth showed a slow-down: the industry's export value increased only 3 percent, dropping 17.4 percentage points when compared with the same period last year. (Click here for more - Chinese language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.